Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN1053 Monotherapy in Advanced Solid Tumors
NCT05435339Phase 2Terminated
- Sponsor
- Genmab
- Start
- Oct 2022
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of GEN1053 in malignant solid tumor, head and neck squamous cell carcinoma (HNSCC), sponsored by Genmab. Started Oct 2022; status: terminated.
02
Drugs
GEN1053
03
Conditions
malignant solid tumorhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05435339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05435339.